Pembro With Radiation With or Without Olaparib
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
- Status
- RECRUITING
- Phase
- PHASE2
Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
- Status
- RECRUITING
- Phase
- PHASE2
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
- Status
- RECRUITING
- Phase
- PHASE2
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2
- Status
- WITHDRAWN
- Phase
- PHASE2
Surgical Pembro +/- Olaparib w TMZ for rGBM
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE4
Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Pilot Trial for Treatment of Recurrent Glioblastoma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE1
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Plus Olaparib in LA-HNSCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
- Status
- RECRUITING
- Phase
- PHASE2